



[Home](#) / [Investors](#) / [News Releases](#)

# Insmmed to Host First Quarter 2013 Financial Results Conference Call on Tuesday, May 7, 2013

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/01/13 -- Insmmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that the Company will release financial results for the three months ended March 31, 2013, before the opening of the stock market on Tuesday, May 7, 2013.

Will Lewis, President and Chief Executive Officer, and Andy Drechsler, Chief Financial Officer, will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, May 7, 2013 to discuss the first quarter 2013 financial results and to answer questions.

Shareholders and other interested parties may participate in the conference call by dialing 888- 803-5993 (domestic) or 706-634-5454 (international) and referencing conference ID number 56371335. The call will also be broadcast live on the internet on the Company's website at [www.insmmed.com](http://www.insmmed.com).

A replay of the conference call will be accessible two hours after its completion through May 13, 2013 by dialing 855-859-2056 (domestic) or 404-537-3406 (international) and referencing conference ID number 56371335. The call will also be archived for 90 days under the Investor Relations section of the Company's website at [www.insmmed.com](http://www.insmmed.com).

## About Insmmed

Insmmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases through the development and commercialization of inhalation therapies in orphan patient populations with critical unmet needs. Insmmed's lead product candidate, ARIKACE® or liposomal amikacin for inhalation, is engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for at least two identified patient populations: cystic fibrosis (CF) patients with *Pseudomonas aeruginosa* lung infections and patients with non-tuberculous mycobacteria (NTM) lung infections. Insmmed's phase 3 registrational study of ARIKACE in Europe and Canada completed enrollment and the Company expects top-line clinical results in mid-2013. Insmmed's phase 2 clinical trial in patients with NTM is well under way in the U.S. and Canada with top-line clinical results expected in late 2013. For more information, please visit <http://www.insmmed.com>.

## Forward-Looking Statements

This release contains forward-looking statements that are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Words, and variations of words, such as "intend," "expect," "will," "anticipate," "believe," "continue," "propose" and similar expressions are intended to identify forward-

looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of results of preclinical studies and clinical trials and preclinical and clinical data and the anticipated benefits of Insmed's products, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation, failure or delay of U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting our product candidates, delays in product development or clinical trials or other studies, patent disputes and other intellectual property developments relating to our product candidates, unexpected regulatory actions, delays or requests, the failure of clinical trials or other studies or results of clinical trials or other studies that do not meet expectations, inability to successfully develop our product candidates or receive necessary regulatory approvals, inability to make product candidates commercially successful, changes in anticipated expenses, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2012. Investors are cautioned not to place undue reliance on any forward-looking statements that speak only as of the date of this news release. We undertake no obligation to update these forward-looking statements to reflect events or circumstances or changes in our expectations.

Investor Relations Contact:

LHA

Anne Marie Fields

Senior Vice President

212-838-3777

[afields@lhai.com](mailto:afields@lhai.com)

Bruce Voss

Managing Director

310-691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)

---